Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
REGENERON PHARMACEUTICALS, INC. (CIK 872589) reported $47.9M across 2 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: NTLA ($47.5M, 99.14%), ACET ($412,080, 0.86%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | NTLA | Intellia Therapeutics, Inc. | $47.5M | 99.14% | 3.7M | Hold |
| 2 | ACET | Adicet Bio, Inc. | $412,080 | 0.86% | 60,511 | Hold |
Source: SEC Form 13F filings · as of 2026-03-31